TCE 或将下一个 BD 风口，建议关注泽璟制 药-U、康诺亚、德琪医药等 增持（维持） [Table_Tag] [Table_Summary] 投资要点 2026 年 03 月 29 日 证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -8% -5% -2% 1% 4% 7% 10% 13% 16% 19% 22% 25% 2025/3/31 2025/7/29 2025/11/26 2026/3/26 医药生物 沪深300 相关研究 《BD 放量及再融资，创新药龙头现金 流充裕》 2026-03-22 《十五五"聚焦脑机接口、首款产品 获批，关注：微创脑科学、翔宇医疗、 爱朋医疗等》 2026-03-15 东吴证券研究所 1 / 30 请务必阅读正文之后的免责声明部分 ◼ 本周、年初至今 A 股医药指数涨跌幅分别为-1.26%、-1.38%，相对沪 深 300 的超额收益分别为 2.31%、1.37%；本周、年初至今恒生生物科 技指数涨跌幅分别为+4.03%、+2.52%，相对于恒生科技指 ...

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 TCE 或将下一个 BD 风口，建议关注泽璟制 药-U、康诺亚、德琪医药等 增持（维持） [Table_Tag] [Table_Summary] 投资要点 2026 年 03 月 29 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -8% -5% -2% 1% 4% 7% 10% 13% 16% 19% 22% 25% 2025/3/31 2025/7/29 2025/11/26 2026/3/26 医药生物 沪深300 相关研究 | 1. 本周及年初至今各医药股收益情况 | 4 | | --- | --- | | 2. TCE：冉冉升起的肿瘤及自免治疗新星 7 | | | 3. 研发进展与企业动态 | 13 | | 3.1. 创新药/改良药研发进展（获批上市/申报上市/获批临床） 13 | | | 3.2. 仿制药及生物类似物上市、临床申报情况 18 | | | 3.3. 重要研发管线一览 24 | | | 4. 行业洞察与监管洞察 | 25 | | 5. 行情回顾 | 25 | | ...

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% this week, ranking 13th out of 31 sectors, and a year-to-date decline of 0.13%, ranking 23rd out of 31 sectors [8]. - A significant milestone was achieved with the approval of the first invasive brain-computer interface medical device by the National Medical Products Administration, marking a transition from technical exploration to clinical application, which opens commercial opportunities in the field of neuroregulation and implantable medical devices [9]. - The launch of a national major scientific research project for innovative drugs targeting Alzheimer's disease indicates the government's commitment to addressing urgent clinical needs in the central nervous system, potentially accelerating technological breakthroughs and industrialization in this area [10]. Company Dynamics - Kanglong Chemical announced a strategic partnership with Eli Lilly for the commercialization of the oral GLP-1 drug Orforglipron, receiving a $200 million investment to enhance its technical capabilities [11]. - Laika Pharmaceuticals successfully completed Phase I SAD studies for LAE102 in the U.S. and is planning Phase II trials, indicating progress in global development [12]. - Hotgen Biotech's innovative drug SGC001 has completed its first administration in Phase II clinical trials for treating acute myocardial infarction, marking a significant advancement in this therapeutic area [13]. - East China Pharmaceutical's self-developed dual-target ADC drug HDM2024 has received FDA approval for Phase I clinical trials in the U.S., enhancing its competitiveness in the oncology field [14]. - Kelun Biotech's SKB575 has been approved for clinical trials targeting atopic dermatitis, showcasing its potential as a best-in-class treatment with a long dosing interval [15]. Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector for potential investment opportunities [16].

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][25]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 2.64% from February 27, 2026, to March 12, 2026, which is approximately 1.81 percentage points lower than the index [11]. - Most sub-sectors within the industry recorded negative returns during the same period, with in vitro diagnostics and medical consumables showing positive growth of 3.49% and 1.71%, respectively, while medical R&D outsourcing and medical devices experienced declines of 4.85% and 4.25% [12]. - Approximately 31% of stocks in the industry recorded positive returns, while 69% experienced negative returns, with notable performers including Shengjitang, which saw a weekly increase of 38.81% [13][16]. - The overall industry valuation has decreased, with the SW pharmaceutical and biotechnology industry index's PE (TTM) at approximately 49.25 times, which is 3.63 times higher than the CSI 300 index [17][25]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 2.64% from February 27, 2026, to March 12, 2026 [11]. - Most sub-sectors recorded negative returns, with in vitro diagnostics and medical consumables performing better [12]. - About 31% of stocks in the industry had positive returns, with significant fluctuations in individual stock performances [16]. 2. Industry News - A new procurement regulation was issued by the Jiangxi Medical Insurance Bureau, aiming to unify the procurement of drugs and medical consumables within county-level medical communities, addressing issues of fragmented management and weak bargaining power [23]. - The Jiangsu Provincial Government released an action plan to promote the development of the brain-computer interface industry, targeting the establishment of several innovative products and companies by 2030 [22]. 3. Company Announcements - Huadong Medicine announced that its subsidiary received FDA approval for a new drug clinical trial, which is a significant milestone for the company [24]. 4. Industry Outlook - The report suggests that the investment risk-reward ratio is improving in the innovation drug sector, recommending attention to various segments including medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, and traditional Chinese medicine [25][26].